|
 |
||||||||||||
| Call for Abstracts |
| Track 1: Practical Solutions to Pharmaceutical Bioequivalence/Bioavailability Implementation |
| Track 1-1: Bioequivalence Strategies in Development-an Industry Perspective |
| Track 1-2: Comparative Bioavailability Studies for New Drugs (NDA) |
| Track 1-3: Comparative Bioavailability Generic Drug Products (ANDA): Bioequivalence Studies |
| Track 1-4: Implementing BA/BE Guidelines and CRO Qualification Criteria |
| Track 2: Pharmacokinetic/Pharmacodynamic Models, Biowaivers and Biosimilars |
| Track 2-1: Human/Animal Models in Oral Drug Absorption |
| Track 2-2: Biosimilars and Biowaivers |
| Track 2-3: Biosimulation in BE Studies-Prediction Tools |
| Track 2-4: Statistical Issues in BA/BE |
| Track 2-5: In Vivo/In Vitro Methods to Determine Bioavailability |
| Track 2-6: Role of Drug Delivery Systems in Bioequivalence and Bioavailability |
| Track 3: Bioanalytical Methodology Development and Validation Using HPLC and LCMS |
| Track 3-1: Advances in Mass Spectrometry Methodology Development |
| Track 3-2: Antiviral, Anti Retroviral, Antibacterial and Anti Fungal Drugs |
| Track 3-3: Drugs Acting on Central Nervous Systems |
| Track 3-4: Anticancer/Anti-Neovascular Drugs |
| Track 4: IP, Regulatory Affairs and Outsourcing Alliance |
| Track 4-1: Clinical Data Harmonization Across Countries |
| Track 4-2: ICH/FDA Guidelines and Regulatory Updates |
| Track 4-3: Partnerships with Animal Research Centres, Universities and Non-Profits |
| Track 4-4: Perspectives of Regulatory Agencies, Worldwide, on Bioequivalence Testing |
| Track 5: Toxicology |
| Track 5-1: Biomarkers in Toxicology |
| Track 5-2: Toxicogenomics & Metabolomics |
| Track 5-3: Environmental Toxicology |
| Track 5-4: Molecular Epidemiology |
| Track 6: PK/PD and Drug Discovery |
| Track 6-1: Anticacer, Antiviral Drug Development |
| Track 6-2: Molecular Drug Targets and Fragment based Drug Design |
| Track 6-3: Improving ADME/DMPK Profile |
| Track 6-4: PK/PD and Bioanalysis Outsourcing Alliance |
| Track 7: Bioavailability |
| Track 7-1: Influence of Disease on Bioavailability |
| Track 7-2: Factors Influencing Bioavailability and Bioequivalence |
| Track 7-3: The Role of Intestinal Metabolism on Bioavailability |
| Track 7-4: In Vitro Methods to Determine Bioavailability & In Vitro-In Vivo Correlations |